490 related articles for article (PubMed ID: 29906416)
1. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.
Musso G; Cassader M; Paschetta E; Gambino R
Gastroenterology; 2018 Aug; 155(2):282-302.e8. PubMed ID: 29906416
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of Nonalcoholic Steatohepatitis.
Machado MV; Diehl AM
Gastroenterology; 2016 Jun; 150(8):1769-77. PubMed ID: 26928243
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Farrell GC; Haczeyni F; Chitturi S
Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
[TBL] [Abstract][Full Text] [Related]
4. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
Musso G; Saba F; Cassader M; Gambino R
Prog Lipid Res; 2023 Jul; 91():101238. PubMed ID: 37244504
[TBL] [Abstract][Full Text] [Related]
5. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease: Insights from sphingolipidomics.
Montefusco DJ; Allegood JC; Spiegel S; Cowart LA
Biochem Biophys Res Commun; 2018 Oct; 504(3):608-616. PubMed ID: 29778532
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Steatohepatitis.
Suzuki A; Diehl AM
Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Manne V; Handa P; Kowdley KV
Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
[TBL] [Abstract][Full Text] [Related]
9. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.
Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H
J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042
[TBL] [Abstract][Full Text] [Related]
10. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
11. Lipid mediators of liver injury in nonalcoholic fatty liver disease.
Liangpunsakul S; Chalasani N
Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G75-G81. PubMed ID: 30383414
[TBL] [Abstract][Full Text] [Related]
12. Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution.
Musso G; Gambino R; Cassader M; Paschetta E; Sircana A
Trends Pharmacol Sci; 2018 Apr; 39(4):387-401. PubMed ID: 29499974
[TBL] [Abstract][Full Text] [Related]
13. STK25 is a critical determinant in nonalcoholic steatohepatitis.
Amrutkar M; Chursa U; Kern M; Nuñez-Durán E; Ståhlman M; Sütt S; Borén J; Johansson BR; Marschall HU; Blüher M; Mahlapuu M
FASEB J; 2016 Oct; 30(10):3628-3643. PubMed ID: 27421788
[TBL] [Abstract][Full Text] [Related]
14. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances.
Cruz-Ramón V; Chinchilla-López P; Ramírez-Pérez O; Méndez-Sánchez N
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s58-s67. PubMed ID: 29080343
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease.
Mato JM; Alonso C; Noureddin M; Lu SC
World J Gastroenterol; 2019 Jun; 25(24):3009-3020. PubMed ID: 31293337
[TBL] [Abstract][Full Text] [Related]
16. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
17. A20 Attenuates FFAs-induced Lipid Accumulation in Nonalcoholic Steatohepatitis.
Ai L; Xu Q; Wu C; Wang X; Chen Z; Su D; Jiang X; Xu A; Lin Q; Fan Z
Int J Biol Sci; 2015; 11(12):1436-46. PubMed ID: 26681923
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans.
Cansby E; Kulkarni NM; Magnusson E; Kurhe Y; Amrutkar M; Nerstedt A; Ståhlman M; Sihlbom C; Marschall HU; Borén J; Blüher M; Mahlapuu M
FASEB J; 2019 Sep; 33(9):9974-9989. PubMed ID: 31173506
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
Carr RM; Oranu A; Khungar V
Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
[TBL] [Abstract][Full Text] [Related]
20. ω-3 Fatty acids reverse lipotoxity through induction of autophagy in nonalcoholic fatty liver disease.
Chen Y; Xu C; Yan T; Yu C; Li Y
Nutrition; 2015; 31(11-12):1423-1429.e2. PubMed ID: 26429665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
